NorthRock Partners LLC Grows Stock Holdings in Gilead Sciences, Inc. $GILD

NorthRock Partners LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,922 shares of the biopharmaceutical company’s stock after purchasing an additional 1,290 shares during the period. NorthRock Partners LLC’s holdings in Gilead Sciences were worth $1,433,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Oregon Public Employees Retirement Fund boosted its stake in shares of Gilead Sciences by 0.5% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 107,541 shares of the biopharmaceutical company’s stock valued at $11,923,000 after purchasing an additional 500 shares in the last quarter. Vest Financial LLC lifted its stake in shares of Gilead Sciences by 39.3% in the second quarter. Vest Financial LLC now owns 14,472 shares of the biopharmaceutical company’s stock worth $1,605,000 after buying an additional 4,080 shares in the last quarter. Welch Group LLC lifted its stake in shares of Gilead Sciences by 29.1% in the second quarter. Welch Group LLC now owns 3,883 shares of the biopharmaceutical company’s stock worth $431,000 after buying an additional 876 shares in the last quarter. Cypress Capital Group lifted its stake in shares of Gilead Sciences by 1.1% in the second quarter. Cypress Capital Group now owns 48,533 shares of the biopharmaceutical company’s stock worth $5,381,000 after buying an additional 551 shares in the last quarter. Finally, Stephens Consulting LLC raised its holdings in shares of Gilead Sciences by 113.7% during the second quarter. Stephens Consulting LLC now owns 3,058 shares of the biopharmaceutical company’s stock valued at $339,000 after purchasing an additional 1,627 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of several research reports. Rothschild & Co Redburn boosted their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective for the company in a research note on Tuesday, August 19th. Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Citigroup increased their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday, October 8th. Finally, UBS Group increased their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.08.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the sale, the chief financial officer owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer directly owned 591,203 shares in the company, valued at approximately $66,013,726.98. This represents a 1.66% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,000 shares of company stock valued at $7,632,100. Insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Up 0.9%

NASDAQ GILD opened at $118.21 on Tuesday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a market capitalization of $146.68 billion, a price-to-earnings ratio of 23.55, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The company’s 50-day simple moving average is $114.72 and its two-hundred day simple moving average is $110.30. Gilead Sciences, Inc. has a one year low of $84.34 and a one year high of $121.83.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s payout ratio is currently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.